Because of the indolent nature of IDH-mutant gliomas, clinical trials of IDH inhibitors in patients with IDH-mutant gliomas have also included patients with recurrent gliomas who received prior therapies.19,20 Furthermore, the small study cohort involved patients with various tumor grades and 1p/19q co-deletion status. Here, IDH1 is linked to neoplasm.